project . 2021 - 2026 . On going

HeartGenes

Next Generation Gene Therapy for the Treatment of Chronic Myocardial Ischemia and Heart Failure
Open Access mandate for Publications European Commission
  • Funder: European CommissionProject code: 884382 Call for proposal: ERC-2019-ADG
  • Funded under: H2020 | ERC | ERC-ADG Overall Budget: 2,500,000 EURFunder Contribution: 2,500,000 EUR
  • Status: On going
  • Start Date
    01 May 2021
    End Date
    30 Apr 2026
  • Detailed project information (CORDIS)
  • Open Access mandate
    Research Data: No
Description
BACKGROUND: Therapeutic angiogenesis has great potential for the treatment of severe heart diseases. However, this requires novel approaches and development of new technology. ADVANCING STATE-OF-THE-ART: We will develop novel VEGF-B and VEGF-C-based gene therapy to treat refractory angina and heart failure (HF). VEGF-B and VEGF-C lead factors were selected from extensive pig studies where they showed the best benefits among all VEGFs, such as relative cardiac specificity, potent angiogenic and metabolic effects (VEGF-B) and lymphangiogenic activity (VEGF-C). Exogenous gene transfer and new endogenous gene activation technology will be developed. Key new technolo...
Partners
Description
BACKGROUND: Therapeutic angiogenesis has great potential for the treatment of severe heart diseases. However, this requires novel approaches and development of new technology. ADVANCING STATE-OF-THE-ART: We will develop novel VEGF-B and VEGF-C-based gene therapy to treat refractory angina and heart failure (HF). VEGF-B and VEGF-C lead factors were selected from extensive pig studies where they showed the best benefits among all VEGFs, such as relative cardiac specificity, potent angiogenic and metabolic effects (VEGF-B) and lymphangiogenic activity (VEGF-C). Exogenous gene transfer and new endogenous gene activation technology will be developed. Key new technolo...
Partners
Any information missing or wrong?Report an Issue